Loading
Metabolism, Diabetes, and Cancer / Cancer, Lipids, and Metabolism / Cancer, Hypoxia, and Metabolism · Journal article
Biomolecules · August 18, 2026
Raises a question worth testing. It does not answer one.
This is a narrative review that synthesizes emerging evidence on shared metabolic dysregulation (glycolysis, OXPHOS, fatty acid oxidation) in cancer and systemic lupus erythematosus, and proposes that targeting these metabolic pathways may offer therapeutic opportunities. The work is exploratory and hypothesis-generating rather than confirmatory, identifying a mechanistic overlap that could motivate cross-disciplinary research and clinical trials.
Journal article. Patients with systemic lupus erythematosus and cancer patients; conceptual overlap in immune cells and malignant cells.
Enhanced glycolysis and OXPHOS have been repeatedly reported in both cancer and SLE Metabolic reprogramming is common in cancer cells and immune cells of SLE patients Cancer cells and B cells in both conditions rely on fatty acid oxidation to generate energy, with upregulation of key enzymes in those processes
No original efficacy or safety data for any specific metabolic therapy reported Applicability and tolerability of cancer-targeted metabolic drugs in SLE patients remains theoretical
This review suggests that metabolic pathway inhibitors developed for cancer may warrant investigation in SLE, and vice versa. However, no clinical trial data or outcome measures are presented; this is a call for collaborative research rather than actionable evidence for practice.
A narrative review synthesizing mechanistic observations about shared metabolic pathways in cancer and SLE, proposing therapeutic hypotheses rather than reporting new empirical evidence or clinical outcomes.
This review suggests that metabolic pathway inhibitors developed for cancer may warrant investigation in SLE, and vice versa. However, no clinical trial data or outcome measures are presented; this is a call for collaborative research rather than actionable evidence for practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
What is missing. This record has no reported figures. That is a gap in the analysis, not a judgement about the study.
Systemic lupus erythematosus (SLE) is a multifaceted autoimmune disease characterized by immune tolerance breakdown, immune cell dysfunction, and chronic inflammation. Cancer is a serious health problem and the second leading cause of mortality worldwide. Emerging evidence underscores the key role of metabolic dysregulation and the association with immunity and immune-related complications in cancer and SLE. Enhanced glycolysis and OXPHOS have been repeatedly reported in both diseases. Metabolic reprogramming is common in cancer cells and immune cells of SLE patients. In many cases, cancer cells and B cells rely on fatty acid oxidation to generate energy. Accordingly, key enzymes in those processes are also upregulated. This review summarizes current findings on major common metabolic dysregulation in cancer and SLE, highlighting the interplay of metabolic disturbances, mitochondrial dysfunction and disease pathogenesis. Furthermore, we explore the potential of targeting metabolic pathways as a therapeutic strategy to mitigate organ damage and improve outcomes in patients with SLE or cancer. We will also discuss the hurdles and prospective developments in metabolism-targeted therapy. We hope this review inspires collaborative work between cancer researchers and SLE clinicians and facilitates clinical application of cancer-metabolism-targeted drug in SLE patients.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.